Table 1.

Baseline characteristics of six patients treated with intravenous high dose immunoglobulins (IVIg) and eight untreated patients with progressive IgAN.

Patient	Age (years)/ gender*	GFR (ml/min per 1·73 m2)*	Loss of renal function (ml/min per month)*	Proteinuria (g/l)*	Serum protein (g/l)*	Blood pressure (mmHg)*	ACE inhibitor (enalapril)¶
IVIg
1	46 m	20	−1·48	3·8	72	140/80	None†
2	50 m	33	−1·19	2·4	72	160/100	10 mg
3	46 m	33	−0·72	2·4	72	160/100	10 mg
4	42 m	17	−0·90	3·2	65	120/80	10 mg
5§	35 m	36	−2·03	1·9	65	140/90	5 mg
6‡	55 m	29	−0·67	1·1	67	140/90	None†
Median	46	31	−1·05	2·4	70	140/90
Control
7	46 m	36	−0·55	2·0	68	150/80	10 mg
8	75 m	19	−1·01	2·4	68	160/80	None†
9	21 m	42	−2·26	2·5	57	130/90	None
10	44 m	40	−2·21	2·4	57	140/100	None
11	54 m	30	−1·18	1·25	66	160/100	10 mg
12	48 m	27	−1·92	2·2	72	180/115	None
13	34 f	25	−0·83	2·4	68	120/100	5 mg
14	53 f	29	−0·77	2·2	63	140/80	10 mg
Median	47	29	−1·09	2·3	67	145/95

ACE: angiotensin converting enzyme. Glomerular filtration rate (GFR) was estimated by the modification of diet in renal disease (MDRD)-2 formula.

^§Patient 5 received cyclophosphamide orally (month 58) after IVIg.

^‡Patient 6 received intravenous cyclophosphamide pulses (CyP) (month 63) after IVIg.

Follow-up period including subsequent cyclophosphamide therapy after IVIg-1 pulse.

^†Chronic cough or hyperkalaemia.

^*Age, GFR, loss of renal function, proteinuria, serum protein and blood pressure were not significantly different between IVIg and the control group in the Mann–Whitney U-test (P > 0·05).

^¶Distribution of the patients with ACE-I between the IVIg and the control group was not significant using the χ² test (P > 0·05); m: male; f: female.